Kuvatris Therapeutics, Inc.

Kuvatris Therapeutics, Inc. (PXMD) priced its initial public offering on Aug 29, 2022 at $5.25 per share, within its $4.50–$6.50 range, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $52.6M. Craft Capital was lead-left underwriter, joined by R.F. Lafferty. Dechert advised the company and Brunson Chandler & Jones advised the underwriters.

Kuvatris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing anti-purinergic drug therapies for disorders with intractable neurologic symptoms, from autism spectrum disorder to myalgic encephalomyelitis/chronic fatigue syndrome. The therapies aim to block the effects of excess ATP signaling in the nervous system.

Status

IPO

Ticker

PXMD

Exchange

Nasdaq Capital Market

Priced

Aug 29, 2022

IPO price

$5.25

Price range

$4.50–$6.50

Market cap at IPO price

$52.6M

First filed

Jul 2, 2020

Underwriters

Craft Capital and R.F. Lafferty

Company counsel

Dechert

Underwriters' counsel

Brunson Chandler & Jones

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.